PMGC Holdings Shares Soar 84% Amid Reverse Split and Acquisition Spree

Introduction

PMGC Holdings Inc. (NASDAQ: ELAB) is a California-based, publicly traded holding company focused on acquiring and operating cash-flowing businesses in the manufacturing and life sciences sectors. As of October 14, 2025, its share price stood at $9.61, with a reported intraday gain of 84.45% on a trading volume of 5,733,004 shares.

Corporate Structure

Founded in 2020, PMGC Holdings operates under a “permanent capital” philosophy, aiming to preserve and grow acquired companies over the long term. Key elements of its structure include:

Wholly owned subsidiaries
- Northstrive Biosciences Inc.
- PMGC Research Inc.
- PMGC Capital LLC
- Elevai Biosciences Inc. (biopharmaceutical R&D)
Management model
- Retention of founders, families, and existing leadership teams
- Central financial and operational support from PMGC’s corporate office

Employee headcount is distributed across subsidiary operations in aerospace CNC machining, specialty metals manufacturing, and biopharma research.

"biopharmaceutical" by CDC

Recent Developments and News

November 20, 2023: Elevai Labs Inc. conducted its IPO on Nasdaq, raising $6 million by selling 1.5 million shares at $4.00 per share under ticker ELAB.
June 30, 2024: Launch of two subsidiaries—Elevai Biosciences, Inc. (focused on obesity-targeting assets EL-22 and EL-32) and Elevai Skincare, Inc. (developing exosome-based medical skincare).
October 2024: Leadership transition at Elevai Labs and corporate name change to PMGC Holdings Inc., accompanied by an $8.0 million public offering.
March 2025: Completion of the sale of Elevai Skincare to Carmell Corporation, generating upfront proceeds and structured royalties.
June 18, 2025: PMGC Capital LLC, a subsidiary of PMGC Holdings, issued a public statement regarding a term sheet for strategic financing with Alaunos Therapeutics (NASDAQ: TCRT).
July 2025: Acquisition of Pacific Sun Packaging, a California-based IT packaging company, with combined revenues reported as exceeding $2 million for fiscal years 2023–2024 and $1.39 million in cash-flow-positive earnings.
August 28, 2025: Announcement of a 1-for-3.5 reverse stock split, effective September 2, 2025, for the company’s issued and authorized common stock (new CUSIP 73017P300).

Financial and Strategic Analysis

PMGC’s capital-raising and M&A activity reflect its approach to portfolio management:

Equity financing: $6 million raised in November 2023; $8 million in October 2024.
Divestiture: Sale of Elevai Skincare improved liquidity and allowed for future revenue through royalties.
Acquisition: Pacific Sun Packaging contributed $2 million in historical revenue and $1.39 million in recurring cash flow, enhancing the manufacturing segment.
Balance-sheet impact: The reverse stock split aims to maintain compliance with Nasdaq requirements and reduce share count volatility without affecting overall shareholder equity.

PMGC’s strategic focus remains on deploying permanent capital to acquire cash-flowing businesses while fostering operational continuity.

Market Position and Industry Context

PMGC Holdings competes in the manufacturing roll-up and life sciences incubation sectors. Its subsidiaries serve end markets including aerospace, defense, and medical skincare. By integrating established founders and management teams, PMGC seeks to balance leadership continuity with operational efficiency. The company’s presence on Nasdaq under the ticker ELAB provides access to public capital, while its diversified portfolio mitigates risks associated with exposure to a single industry.

tl;dr

On September 2, 2025, PMGC Holdings completed a 1-for-3.5 reverse stock split to reduce its share count and maintain Nasdaq listing standards. In Q2 2025, the company acquired Pacific Sun Packaging—bringing $2 million in historical revenues and $1.39 million in cash flow—while earlier proceeds from the sale of Elevai Skincare improved liquidity. PMGC continues to pursue acquisitions under its permanent capital model, with potential opportunities across manufacturing and biopharmaceutical assets.